A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

NCT07321093 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

292

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing-remitting Multiple Sclerosis (RRMS)

Interventions

BIOLOGICAL: BCD-281
BIOLOGICAL: Ocrelizumab

Sponsor

Biocad